{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:55:42Z","timestamp":1765547742193,"version":"3.48.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"DOI":"10.7759\/cureus.99044","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:52:37Z","timestamp":1765547557000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Saroglitazar in Improving Transient Elastography Parameters in Significant and Advanced Metabolic Dysfunction-Associated Steatohepatitis"],"prefix":"10.7759","author":[{"given":"Manish C","family":"Kak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis","volume":"12","author":"Shalimar","year":"2022","unstructured":"Shalimar, Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. J Clin Exp Hepatol. 2022, 12:818-29. 10.1016\/j.jceh.2021.11.010","journal-title":"J Clin Exp Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15730","article-title":"A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies","volume":"44","author":"Forlano R","year":"2024","unstructured":"Forlano R, Stanic T, Jayawardana S, et al.. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int. 2024, 44:61-71. 10.1111\/liv.15730","journal-title":"Liver Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: a meta-analysis","volume":"134","author":"Friedrich-Rust M","year":"2008","unstructured":"Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008, 134:960-74. 10.1053\/j.gastro.2008.01.034","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21420","article-title":"Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases","volume":"44","author":"Ganne-Carri\u00e9 N","year":"2006","unstructured":"Ganne-Carri\u00e9 N, Ziol M, de Ledinghen V, et al.. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006, 44:1511-17. 10.1002\/hep.21420","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0115","article-title":"Nonalcoholic fatty liver disease: a drug revolution is coming","volume":"44","author":"Jeong SW","year":"2020","unstructured":"Jeong SW. Nonalcoholic fatty liver disease: a drug revolution is coming. Diabetes Metab J. 2020, 44:640-57. 10.4093\/dmj.2020.0115","journal-title":"Diabetes Metab J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00055","article-title":"Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail","volume":"9","author":"Sharma M","year":"2021","unstructured":"Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail. J Clin Transl Hepatol. 2021, 9:40-50. 10.14218\/JCTH.2020.00055","journal-title":"J Clin Transl Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013156.pub2","article-title":"Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis","volume":"6","author":"Buzzetti E","year":"2021","unstructured":"Buzzetti E, Linden A, Best LM, et al.. Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev. 2021, 6:CD013156. 10.1002\/14651858.CD013156.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/nu11122971","article-title":"Mediterranean diet and NAFLD: what we know and questions that still need to be answered","volume":"11","author":"Plaz Torres MC","year":"2019","unstructured":"Plaz Torres MC, Aghemo A, Lleo A, et al.. Mediterranean diet and NAFLD: what we know and questions that still need to be answered. Nutrients. 2019, 11:2971. 10.3390\/nu11122971","journal-title":"Nutrients"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Le MH","year":"2024","unstructured":"Le MH, Le DM, Baez TC, et al.. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Mol Hepatol. 2024, 30:235-46. 10.3350\/cmh.2023.0485","journal-title":"Clin Mol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v10i2.3941","article-title":"The clinical aspects of saroglitazar and its side effects","volume":"10","author":"Sai VN","year":"2020","unstructured":"Sai VN, Pasula S, Sumathi S, et al.. The clinical aspects of saroglitazar and its side effects. J Drug Deliv Ther. 2020, 10:208-12. 10.22270\/jddt.v10i2.3941","journal-title":"J Drug Deliv Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal O","year":"2020","unstructured":"Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020, 10:21117. 10.1038\/s41598-020-78342-x","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience","volume":"7","author":"Chaudhuri S","year":"2023","unstructured":"Chaudhuri S, Dutta A, Chakraborty SB. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience. JGH Open. 2023, 7:215-20. 10.1002\/jgh3.12878","journal-title":"JGH Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients","volume":"12","author":"Padole P","year":"2022","unstructured":"Padole P, Arora A, Sharma P, Chand P, Verma N, Kumar A. Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients. J Clin Exp Hepatol. 2022, 12:435-9. 10.1016\/j.jceh.2021.06.015","journal-title":"J Clin Exp Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439278-role-of-saroglitazar-in-improving-transient-elastography-parameters-in-significant-and-advanced-metabolic-dysfunction-associated-steatohepatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:52:37Z","timestamp":1765547557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439278-role-of-saroglitazar-in-improving-transient-elastography-parameters-in-significant-and-advanced-metabolic-dysfunction-associated-steatohepatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.99044","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}